Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 11/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088012 | 1.00 | ALDH1A1 (0.49) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL23088260 | 0.87 | KDM4E (0.50) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL17232476 | 0.85 | ALDH1A1 (0.46) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL17221463 | 0.83 | ALDH1A1 (0.45) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL23139787 | 0.81 | ALDH1A1 (0.50) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL17229331 | 0.81 | AR (0.46) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL27033473 | 0.80 | ALDH1A1 (0.43) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL17221721 | 0.80 | CD274 (0.44) | KDM4EHTR2AMAOBCD274HTR2C | |
| SCHEMBL9723166 | 0.78 | ALDH1A1 (0.53) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL20549323 | 0.77 | IMPDH2 (0.43) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2025-03-06 | — | — | US | disclosed |
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | ALDH1A1 3143/4885IMPDH2 4449/4885IMPDH1 4083/4885 |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | ALDH1A1 3143/4885IMPDH2 4449/4885IMPDH1 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.